contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


biohit-sustainability-turnaround-being-tested

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Biohit operates in the medical technology sector. The company develops and manufactures laboratory equipment, consumables and diagnostic analysis systems adapted for research, healthcare and industrial laboratories. In addition to its main business, it offers technical support, maintenance and training services within the aforementioned field of work. The largest operations are conducted in the Nordic market. The company has its headquarters in Helsinki.

We did a quick update on Biohit with Antti.                    Inderes              Biohit kasvaa ja kannattaa - Inderes    Aika: 27.01.2026 klo 16.37 Biohitin osake sekä liiketoiminta ovat kehittyneet erinomaisesti viimeisen kolmen vuoden aikana. Onko osakkeessa vielä potentiaalia?

H1 revenue was €7.4M and did not grow from the previous year. H2 2024 was €6.9M. Reaching even the lower end of the guidance at €15.7M would mean over 20% revenue growth for the rest of the year (H2 > €8.3M). This would also bode well for the results.

Three weeks since the turn of the year and no negative profit warning has been issued, at least not yet. Revenue guidance for last year was 15.7–17.1M. Inderes’ revenue estimate, raised a week ago, is right at the lower end of the guidance at 15.7M. My expectations for H2 are rising, at least personally.

Antti has written a new company report on Biohit.  Biohit’s share price has declined and, as a result, the risk/reward ratio has turned attractive again. We are upgrading our recommendation to Accumulate (prev. Reduce) and reiterating our target price of EUR 3.7. There have been no changes to the company’s outlook, but we are making minor adjustments to our forecasts for the coming years. The changes have no material significance for the valuation. For the current year, we expect Biohit to continue its defensive profitable growth. Uncertainty for the year is created by the situation in the Middle East and the development of accounts receivable.                   Inderes              Tartumme Biohitin tammialeen - Inderes    Biohitin osakekurssi on laskenut ja sen myötä tuotto-riskisuhde on kääntynyt jälleen houkuttelevaksi.

Well that explains a bit, thanks for this! Doesn’t give me the chills after all.

Hendolin held management positions at Biohit during 2007–2008, 2014–2017, and 2022–2026, so he has certainly managed to do a lot for the company, even though he was in his most recent role for only a year and a half.

https://www.inderes.fi/releases/muutos-biohitin-johtoryhmassa. Well, at least there’s some news for a change. They served in the role for a disappointingly short time; it would be interesting to know if this is an indicator and of what exactly

Biohit

Biohit is focused on diagnostics of the gastrointestinal tract and health-promoting products. The company has shown the first signs of a turnaround after a long loss-making period.

<p>Biohit is focused on diagnostics of the gastrointestinal tract and health-promoting products. The company has shown the first signs of a turnaround after a long loss-making period. We feel a permanent turnaround of the result is likely thanks to new products, the renewed Chinese distribution agreement and effective implementation of the strategy. We believe that the development of new products and successful commercialization are key to the company's long-term success.</p> 

	2022	23e	24e
Revenue	11.0	11.3	12.6
growth-%	17.0 %	3.2 %	11.5 %
EBIT (adj.)	1.1	1.2	1.6
EBIT-% (adj.)	10.3 %	10.9 %	12.4 %
EPS (adj.)	0.04	0.07	0.09
Dividend	0.00	0.00	0.05
Dividend %			1.5 %
P/E (adj.)	39.3	48.8	36.9
EV/EBITDA	11.4	25.7	21.1

Biohit: Sustainability of turnaround being tested

Key Estimate Figures30.06.2023

Forum discussions